孟鲁司特联合布地奈德治疗中度哮喘的临床研究

目的：观察孟鲁司特联合布地奈德治疗中度哮喘的临床疗效。方法：选取中度哮喘急性发作患者60例,随机分为3组,孟鲁司特组（10mg/d）,布地奈德组（200-400μg/d）,孟鲁司特＋布地奈德组（5mg/d＋200-400μg/d）各20例。记录患者哮喘症状并评分;观察三组的临床症状缓解程度及时间,测定治疗前及治疗8周后的肺功能状态。结果：孟鲁司特联合吸入布地奈德组白天、夜间哮喘发作均弱于两药单独使用组,孟鲁司特联合吸入布地奈德组咳嗽、喘息、胸闷等临床症状缓解时间明显短于单独使用组,肺功能状态得道明显改善。结论：孟鲁司特联合吸入布地奈德可以显著缓解中度哮喘患者的哮喘症状,值得临床大力推广及积极应用。

Clinical Research on the Treatment of Montelukast Combined with Budesonide for Moderate Asthma

Objective：To study the clinical efficacy of montelukast associated with budesonide on moderate asthma patients.Method：60 moderate asthma patients were involved in the present trial.The cases were randomly divided into 3 groups.Montelukast group （10 mg·d-1）,budesonide group （200～400 μg·d-1） and montelukast associated with budesonide group （5 mg·d-1 ＋ 200～400 μg·d-1）,20 cases in each.The clinical efficacy of the therapy was observed.Results：There was significant amelioration concerning the forced expiratory volume in one second （FEV1） and peak expiratory flow （PEF） in Montelukast associated with budesonide group.Meanwhile,the score of the asthma symptom of the day and night was significantly reduced.Conclusion：The treatment of montelukast associated with budesonide is more effective than used respectively.Montelukast associated with budesonide can be used to treat moderate asthma effectively.